ATHE
Get informed when a big investor buys or sells
+ FollowOvervalued by 45.6% based on the discounted cash flow analysis.
| Market cap | $87.00 Million |
|---|---|
| Enterprise Value | $49.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.32 |
| Beta | -0.03 |
| Outstanding Shares | 18,125,738 |
| P/E Ratio | -3.22 |
|---|---|
| PEG | -1.78 |
| Price to Sales | - |
| Price to Book Ratio | 1.36 |
| Enterprise Value to Revenue | 10.76 |
| Enterprise Value to EBIT | -1.27 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 2.18%▲ 0.29% |
|---|---|
| Total Invested | $2.12M▲ 89.47% |
| Investors Holding | 22▲ 7.00% |
No data
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among oth...